Remove 2015 Remove FDA Approval Remove Pharmaceuticals
article thumbnail

Nevakar Announces FDA Approval for Ephedrine Sulfate Injection as Ready-to-Use Vials

The Pharma Data

Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation. Under an exclusive licensing agreement with Endo International’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, Par Pharmaceuticals’ Sterile Products division will launch and distribute the product.

article thumbnail

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The Pharma Data

Founded in 2015, Standigm has raised $23M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

The Pharma Data

“By committing to bring biosimilar formulations such as Hyrimoz citrate-free HCF to patients, we are serving a critical need in expanding access to important medicines and fueling pharmaceutical innovation.”. The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL.

article thumbnail

Announcing the first biopharma IPNFT Transaction

Molecule Blog

Announcing the first biopharma IP-NFT Transaction Funding the first longevity research project by utilizing intellectual property NFTs in the pharmaceutical space Summary The vote has passed, the decision is made: The Scheibye-Knudsen Lab will be the first research organisation to fund their longevity research via an IPNFT.

article thumbnail

Another Milestone in the Cystic Fibrosis Journey

NIH Director's Blog: Drug Development

According to preliminary data from one Phase 1 and two Phase 2 clinical trials reported by Vertex Pharmaceuticals Inc., The first major advance in molecularly targeted drug treatment for the disease came in 2012, when the Food and Drug Administration (FDA) approved ivacaftor (Kalydeco). About 30,000 Americans have CF.

article thumbnail

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

The Pharma Data

The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL. 1 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval. A: For FDA 1572 is a Statement of Investigator under US Regulations/Laws. of this guidance.